SCHEMBL1873733

SCHEMBL1873733

O=Cc1ccc(N2CCCCC2)c(F)c1

nearest known ligand 0.97

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.97
SMN1; SMN2 Q16637 4/20 0.97
ALDH1A3 P47895 6/20 0.66
MAPT P10636 7/20 0.60
MITF O75030 1/20 0.60
HSP90AA1 P07900 1/20 0.60
HTT P42858 1/20 0.60
KDM4E B2RXH2 1/20 0.53
HPGD P15428 3/20 0.50
TSHR P16473 1/20 0.50
TRIM24 O15164 1/20 0.50
TRIM33 Q9UPN9 1/20 0.50
RAB9A P51151 4/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
NPC1 O15118 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
ALDH3A1 P30838 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29728056 1.00 ALDH1A1 (0.97) ALDH1A1SMN1; SMN2ALDH1A3MAPTMITF
SCHEMBL15094164 0.98 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2ALDH1A3MAPTMITF
SCHEMBL29728058 0.98 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2ALDH1A3MAPTMITF
SCHEMBL15264110 0.86 ALDH1A1 (0.77) ALDH1A1SMN1; SMN2ALDH1A3MAPTMITF
SCHEMBL31494990 0.83 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2ALDH1A3MAPTMITF
SCHEMBL4934676 0.83 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2ALDH1A3MAPTMITF
SCHEMBL6223764 0.83 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2ALDH1A3MAPTMITF
SCHEMBL19137930 0.83 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2ALDH1A3MAPTMITF
SCHEMBL7141451 0.83 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2ALDH1A3MAPTMITF
SCHEMBL5466015 0.83 ALDH1A1 (0.68) ALDH1A1SMN1; SMN2ALDH1A3MAPTMITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110590796-B Camptothecin derivative and preparation method and application thereof 青岛海洋生物医药研究院股份有限公司 2022-07-15 CN disclosed
US-20220177485-A1 CAMPTOTHECIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF MARINE BIOMEDICAL RESEARCH INSTITUTE OF QINGDAO CO., LTD. (CN) 2022-06-09 US disclosed
EP-3808751-A1 CAMPTOTHECIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Marine Biomedical Research Institute Of Qingdao Co., Ltd. (CN) 2021-04-21 EP disclosed
CN-110590796-A Camptothecin derivative and preparation method and application thereof 青岛海洋生物医药研究院股份有限公司 2019-12-20 CN disclosed
WO-2019238046-A1 CAMPTOTHECIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 青岛海洋生物医药研究院股份有限公司 2019-12-19 WO disclosed
US-8513253-B2 α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-20 US disclosed
US-20110105485-A1 Alpha-(N-Sulfonamido)Acetamide Derivatives as Beta-Amyloid Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2011-05-05 US disclosed
US-7786122-B2 α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-08-31 US disclosed
WO-2009109998-A1 NOVEL PROTEIN TYROSINE PHOSPHATASE - IB INHIBITORS LUPIN LIMITED (IN) 2009-09-11 WO disclosed
EP-1465861-B1 ALPHA-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2009-05-06 EP disclosed
US-20080085894-A1 ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2008-04-10 US disclosed
US-7300936-B2 α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-27 US disclosed
CN-1289469-C Alpha-(n-sulphonamido)acetamide derivatives as beta-amyloid inhibitors BRISTOL MYERS SQUIBB CO (US) 2006-12-13 CN disclosed
EP-1465861-A4 ALPHA-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2005-12-07 EP disclosed
CN-1617852-A Alpha- (N-sulfonamido) acetamide derivatives as beta-amyloid inhibitors BRISTOL MYERS SQUIBB CO (US) 2005-05-18 CN disclosed
EP-1465861-A1 ALPHA-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS Bristol-Myers Squibb Company (US) 2004-10-13 EP disclosed
US-20040127494-A1 Alpha-(N-sulfonamido)acetamide derivatives as beta-amyloid inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-07-01 US disclosed
WO-2003053912-A1 α-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS β-AMYLOID INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085894-A1 ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS APP, APBA1, BACE1 ALDH1A1 1197/4885SMN1; SMN2 675/4885ALDH1A3 2043/4885
US-20220177485-A1 CAMPTOTHECIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF WEE1, WASF2, WEE2 ALDH1A1 699/4885SMN1; SMN2 4052/4885ALDH1A3 1644/4885
US-20110105485-A1 Alpha-(N-Sulfonamido)Acetamide Derivatives as Beta-Amyloid Inhibitors APP, APBA1, BACE1 ALDH1A1 1197/4885SMN1; SMN2 675/4885ALDH1A3 2043/4885
US-20040127494-A1 Alpha-(N-sulfonamido)acetamide derivatives as beta-amyloid inhibitors APBA1, APP, BACE1 ALDH1A1 1482/4885SMN1; SMN2 490/4885ALDH1A3 2155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.